Kopran manufactures and exports pharmaceutical ingredients and finished medicines like antibiotics and heart medications, while also providing diagnostic equipment and testing chemicals to hospitals and labs.
The company lacks a significant moat, as evidenced by low average ROE (7.6%) and net margins (5.5%). While they have a 'reagent rental' model in diagnostics that creates some switching costs, their core pharma business is largely in commoditized generics and APIs facing intense Chinese price competition.
Management has prioritized vertical integration and capacity expansion, notably the Panoli API facility. However, the EPS CAGR of -7.0% despite revenue growth suggests that reinvested capital has not yet translated into per-share value for owners.
The investment failed because the company remained a 'treadmill' business, where revenue growth required constant capital expenditure that never translated into bottom-line earnings. Despite expanding capacity at Panoli, the lack of pricing power meant that Chinese competitors simply undercut the new volume, keeping net margins razor-thin. The negative EPS growth observed in the initial data persisted as foreign exchange volatility and rising input costs for key starting materials swallowed the remaining cash flow, leaving shareholders with a business that grew in size but shrank in per-share value.
RichFakir rates Kopran Ltd's business quality as poor — 35/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Kopran Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Kopran Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Kopran Ltd's fair value is about ₹84 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →